These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
323 related articles for article (PubMed ID: 30232145)
21. Biallelic somatic SMARCA4 mutations in small cell carcinoma of the ovary, hypercalcemic type (SCCOHT). Bailey S; Murray MJ; Witkowski L; Hook E; Hasselblatt M; Crawford R; Foulkes WD; Tischkowitz M; Nicholson JC Pediatr Blood Cancer; 2015 Apr; 62(4):728-30. PubMed ID: 25307865 [TBL] [Abstract][Full Text] [Related]
22. Loss of SMARCA4 Expression Is Both Sensitive and Specific for the Diagnosis of Small Cell Carcinoma of Ovary, Hypercalcemic Type. Conlon N; Silva A; Guerra E; Jelinic P; Schlappe BA; Olvera N; Mueller JJ; Tornos C; Jungbluth AA; Young RH; Oliva E; Levine D; Soslow RA Am J Surg Pathol; 2016 Mar; 40(3):395-403. PubMed ID: 26645725 [TBL] [Abstract][Full Text] [Related]
23. Epigenetic and molecular mechanisms underlying the antileukemic activity of the histone deacetylase inhibitor belinostat in human acute promyelocytic leukemia cells. Savickiene J; Treigyte G; Valiuliene G; Stirblyte I; Navakauskiene R Anticancer Drugs; 2014 Sep; 25(8):938-49. PubMed ID: 24800886 [TBL] [Abstract][Full Text] [Related]
24. Precision Targeting with EZH2 and HDAC Inhibitors in Epigenetically Dysregulated Lymphomas. Lue JK; Prabhu SA; Liu Y; Gonzalez Y; Verma A; Mundi PS; Abshiru N; Camarillo JM; Mehta S; Chen EI; Qiao C; Nandakumar R; Cremers S; Kelleher NL; Elemento O; Amengual JE Clin Cancer Res; 2019 Sep; 25(17):5271-5283. PubMed ID: 30979734 [TBL] [Abstract][Full Text] [Related]
25. Germline mutations of SMARCA4 in small cell carcinoma of the ovary, hypercalcemic type and in SMARCA4-deficient undifferentiated uterine sarcoma: Clinical features of a single family and comparison of large cohorts. Connor YD; Miao D; Lin DI; Hayne C; Howitt BE; Dalrymple JL; DeLeonardis KR; Hacker MR; Esselen KM; Shea M Gynecol Oncol; 2020 Apr; 157(1):106-114. PubMed ID: 31954538 [TBL] [Abstract][Full Text] [Related]
26. Immune-Active Microenvironment in Small Cell Carcinoma of the Ovary, Hypercalcemic Type: Rationale for Immune Checkpoint Blockade. Jelinic P; Ricca J; Van Oudenhove E; Olvera N; Merghoub T; Levine DA; Zamarin D J Natl Cancer Inst; 2018 Jul; 110(7):787-790. PubMed ID: 29365144 [TBL] [Abstract][Full Text] [Related]
27. c-Met inhibitors attenuate tumor growth of small cell hypercalcemic ovarian carcinoma (SCCOHT) populations. Otte A; Rauprich F; von der Ohe J; Yang Y; Kommoss F; Feuerhake F; Hillemanns P; Hass R Oncotarget; 2015 Oct; 6(31):31640-58. PubMed ID: 26436697 [TBL] [Abstract][Full Text] [Related]
28. Small Cell Carcinoma of Ovary, Hypercalcemic Type: A Rare Case Report. Coşkun Ç; Kurucu N; Usubutun A; Soyer T; Ozcan HN; Çelik Ertaş NB; Kutluk T J Pediatr Adolesc Gynecol; 2023 Apr; 36(2):112-115. PubMed ID: 36243275 [TBL] [Abstract][Full Text] [Related]
29. Arginine Depletion Therapy with ADI-PEG20 Limits Tumor Growth in Argininosuccinate Synthase-Deficient Ovarian Cancer, Including Small-Cell Carcinoma of the Ovary, Hypercalcemic Type. Ji JX; Cochrane DR; Tessier-Cloutier B; Chen SY; Ho G; Pathak KV; Alcazar IN; Farnell D; Leung S; Cheng A; Chow C; Colborne S; Negri GL; Kommoss F; Karnezis A; Morin GB; McAlpine JN; Gilks CB; Weissman BE; Trent JM; Hoang L; Pirrotte P; Wang Y; Huntsman DG Clin Cancer Res; 2020 Aug; 26(16):4402-4413. PubMed ID: 32409304 [TBL] [Abstract][Full Text] [Related]
30. Histone Deacetylase (HDAC) Inhibition Induces IκB Kinase (IKK)-dependent Interleukin-8/CXCL8 Expression in Ovarian Cancer Cells. Gatla HR; Zou Y; Uddin MM; Singha B; Bu P; Vancura A; Vancurova I J Biol Chem; 2017 Mar; 292(12):5043-5054. PubMed ID: 28167529 [TBL] [Abstract][Full Text] [Related]
31. The hereditary nature of small cell carcinoma of the ovary, hypercalcemic type: two new familial cases. Witkowski L; Donini N; Byler-Dann R; Knost JA; Albrecht S; Berchuck A; McCluggage WG; Hasselblatt M; Foulkes WD Fam Cancer; 2017 Jul; 16(3):395-399. PubMed ID: 27866340 [TBL] [Abstract][Full Text] [Related]
32. Small-Cell Carcinoma of the Ovary, Hypercalcemic Type-Genetics, New Treatment Targets, and Current Management Guidelines. Tischkowitz M; Huang S; Banerjee S; Hague J; Hendricks WPD; Huntsman DG; Lang JD; Orlando KA; Oza AM; Pautier P; Ray-Coquard I; Trent JM; Witcher M; Witkowski L; McCluggage WG; Levine DA; Foulkes WD; Weissman BE Clin Cancer Res; 2020 Aug; 26(15):3908-3917. PubMed ID: 32156746 [TBL] [Abstract][Full Text] [Related]
33. Small cell carcinoma of the ovary, hypercalcemic type, displays frequent inactivating germline and somatic mutations in SMARCA4. Ramos P; Karnezis AN; Craig DW; Sekulic A; Russell ML; Hendricks WP; Corneveaux JJ; Barrett MT; Shumansky K; Yang Y; Shah SP; Prentice LM; Marra MA; Kiefer J; Zismann VL; McEachron TA; Salhia B; Prat J; D'Angelo E; Clarke BA; Pressey JG; Farley JH; Anthony SP; Roden RB; Cunliffe HE; Huntsman DG; Trent JM Nat Genet; 2014 May; 46(5):427-9. PubMed ID: 24658001 [TBL] [Abstract][Full Text] [Related]
34. Identification of Driver Mutations in Rare Cancers: The Role of SMARCA4 in Small Cell Carcinoma of the Ovary, Hypercalcemic Type (SCCOHT). Lang JD; Hendricks WPD Methods Mol Biol; 2018; 1706():367-379. PubMed ID: 29423809 [TBL] [Abstract][Full Text] [Related]
35. A Population-Based Study of Patients With Small Cell Carcinoma of the Ovary, Hypercalcemic Type, Encompassing a 30-Year Period. Blatnik A; Dragoš VŠ; Blatnik O; Stegel V; Klančar G; Novaković S; Drev P; Žagar T; Merlo S; Škof E; Bojadžiski MP; Strojnik K; Krajc M Arch Pathol Lab Med; 2024 Mar; 148(3):299-309. PubMed ID: 37270804 [TBL] [Abstract][Full Text] [Related]
36. The influence of clinical and genetic factors on patient outcome in small cell carcinoma of the ovary, hypercalcemic type. Witkowski L; Goudie C; Ramos P; Boshari T; Brunet JS; Karnezis AN; Longy M; Knost JA; Saloustros E; McCluggage WG; Stewart CJR; Hendricks WPD; Cunliffe H; Huntsman DG; Pautier P; Levine DA; Trent JM; Berchuck A; Hasselblatt M; Foulkes WD Gynecol Oncol; 2016 Jun; 141(3):454-460. PubMed ID: 26975901 [TBL] [Abstract][Full Text] [Related]
37. Small cell ovarian carcinoma: genomic stability and responsiveness to therapeutics. Gamwell LF; Gambaro K; Merziotis M; Crane C; Arcand SL; Bourada V; Davis C; Squire JA; Huntsman DG; Tonin PN; Vanderhyden BC Orphanet J Rare Dis; 2013 Feb; 8():33. PubMed ID: 23433318 [TBL] [Abstract][Full Text] [Related]
38. Recurrent SMARCA4 mutations in small cell carcinoma of the ovary. Jelinic P; Mueller JJ; Olvera N; Dao F; Scott SN; Shah R; Gao J; Schultz N; Gonen M; Soslow RA; Berger MF; Levine DA Nat Genet; 2014 May; 46(5):424-6. PubMed ID: 24658004 [TBL] [Abstract][Full Text] [Related]
39. Additional Considerations on Aberrant BRG1 (SMARCA4) Expression in Small Cell Carcinoma of the Ovary, Hypercalcemic Type (SCCOHT). Cyrta J; Brillet R; Laas E; Just PA; Andrianteranagna M; Leary A; Vincent-Salomon A; Bourdeaut F; Masliah-Planchon J Am J Surg Pathol; 2024 Oct; 48(10):1335-1338. PubMed ID: 39092991 [No Abstract] [Full Text] [Related]